MK-677 vs Semaglutide for appetite
Short answer: For appetite, more users report improvement with Semaglutide — 80% of 70 reports, versus 66% of 228 for MK-677.
MK-677 has 0 meta-analyses and 15 randomized trials on PubMed; Semaglutide has 421 and 307.
Based on 978 reports about MK-677 and 330 about Semaglutide. Not medical advice.
| MK-677 Substance | Semaglutide Medication | |
|---|---|---|
| Users say it helped | 39%helped479 reports · high confidence | 64%helped228 reports · high confidence |
| Verdict | Mixed | Mostly positive |
| Research | BResearch: Moderate | AResearch: Strong |
| Meta-analyses / RCTs | 0 / 15 | 421 / 307 |
| Mainly used for | ||
| Appetite % reporting improvement | 66% (228) | 80% (70) |
| Weight loss % reporting improvement | 53% (55) | 85% (138) |
| Sleep % reporting improvement | 79% (170) | 50% (4) |
| Recovery % reporting improvement | 99% (106) | 100% (2) |
| Performance % reporting improvement | 90% (87) | 83% (6) |
| Common side effects | water retention, fatigue, stomach issues, hunger | nausea, fatigue, stomach issues, constipation |
| Typical dose reported | 12.5 mg / before dinner | Not listed |
MK-677Full MK-677 profile →
What a user said
“From my own experience (also have suffered from poor sleep), i experienced a noticeable increase in sleep quality even with a low dose.”
SemaglutideFull Semaglutide profile →
Latest review conclusion
This study shows that new anti-diabetic drugs, particularly GLP1-RA and Tirzepatide, are the most effective in inducing weight loss in patients with type 2 diabetes. Interestingly, exenatide appears to be the only GLP1-RA that induces a mild weight loss.
Pharmacol Res, 2021 ↗What a user said
“I've lost 35lbs since then and now I'm in the Healthy range on BMI. My IBSD has virtually disappeared.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate